Building a Global Price Strategy: How Thelansis Helped a Biopharma Set the Right Launch Price Across 15 Markets
Background: A biopharma company was preparing to launch a first-in-class therapy in immunology TA. The asset showed strong clinical promise, but its commercial team faced a familiar challenge: every ...
The US-UK Drug Pricing Deal: What It Means for Both Countries and the Global Market
For years, the United States and the United Kingdom have stood on opposite ends of the drug pricing spectrum. The US has historically allowed manufacturers to set list prices with relatively few const ...
Optimizing Biotech Investment Strategy in an Uncertain Market Landscape
Introduction: A US-based mid-size biotech firm was preparing for its upcoming investment cycle to broaden its therapeutic area focus. The team had strong scientific instincts but lacked a unified, ev ...